Business Context and Reporting Period
AC Immune SA, a Swiss foreign private issuer, filed this Form 6-K for October 2026. It reports the outcome of an Extraordinary General Meeting held on October 2, 2026.
Financial Performance and Position
This filing contains no revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics.
Material Event
Shareholders approved Tom Graney’s election to the Board of Directors through the end of the 2027 Annual General Meeting.
Outlook, Risks, and Other Items
The filing provides no financial guidance, outlook, management commentary, or new risk or contingency disclosures. AC Immune said meeting minutes would be published on its website within 15 days. The report is incorporated by reference into specified Form F-3 and Form S-8 registration statements.
Important Facts to Verify
- Review the meeting minutes on AC Immune’s investor relations website for further details of the vote.
- Confirm Tom Graney’s Board service term and any subsequent governance updates.